002462 Cachet Pharmaceutical
- 10.81
- +0.15+1.41%
Cachet Pharmaceutical News
Cachet Pharmaceutical: Legal Opinion of OnLee Law Firm Concerning the Second Extraordinary General Meeting of Shareholders of Cachet Pharmaceuticals in 2024.
Cachet Pharmaceutical: Announcement of resolution of the Second Extraordinary Shareholders' Meeting in 2024.
Cachet Pharmaceutical: Announcement regarding the resignation of the company's director.
Cachet Pharmaceutical: Notice of convening the second extraordinary shareholder meeting in 2024.
Cachet Pharmaceutical: Announcement Regarding Changing the Accounting Firm.
Cachet Pharmaceutical: Announcement of the Resolution of the Tenth Interim Meeting of the Seventh Board of Directors.
Cachet Pharmaceutical: Announcement of the resolution of the seventh temporary meeting of the seventh supervisory board.
Cachet Pharmaceutical: The board of directors' audit committee report on the accounting firm's performance evaluation and supervision duty fulfillment in the year 2023.
Cachet Pharmaceutical: Cachet Pharmaceutical's 2023 Annual Stock Equity Distribution Implementation Announcement.
Cachet Pharmaceutical: Related Transactions Management Measures (2024 Revision)
Cachet Pharmaceutical: Independent Director Work System (2024 Revised Edition)
Cachet Pharmaceutical: Security Law Firm's Legal Opinion on Jiashitang's 2023 Annual General Meeting of Shareholders
Cachet Pharmaceutical: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Cachet Pharmaceutical: Announcement on changing the company's employee representative supervisors
Cachet Pharmaceutical: 2023 Independent Director Debriefing Report (Zhang Haiyan)
Cachet Pharmaceutical: Announcement of Board Resolutions
Cachet Pharmaceutical: Announcement on the 2023 Profit Distribution Plan
Cachet Pharmaceutical: Notice on applying for a comprehensive credit line for 2024 from banks
Cachet Pharmaceutical: 2023 Independent Director Debriefing Report (Xiong Yan)
Cachet Pharmaceutical: Notice of Annual General Meeting of Shareholders
Analysis
Price Target
No Data
